Sexually transmitted disease surveillance 2003 supplement : Gonococcal Isolate Surveillance Project (GISP) annual report, 2003
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields



Document Data
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page


Sexually transmitted disease surveillance 2003 supplement : Gonococcal Isolate Surveillance Project (GISP) annual report, 2003

Filetype[PDF-507.05 KB]



  • Alternative Title:
    Gonococcal Isolate Surveillance Project (GISP) annual report, 2003;GISP 2003 surveillance supplement;
  • Personal Author:
  • Corporate Authors:
  • Description:
    "With 335,104 gonorrhea cases reported in 2003, gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.8% during 1975-1997. After a small increase in the rate in 1998, the gonorrhea rate has decreased 10.1% since 1999 to the current rate of 116.2 per 100,000 persons. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea facilitates HIV transmission. The treatment and control of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial agents. The appearance of penicillinase-producing N. gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC-recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins (ceftriaxone and cefixime), and three fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). However, since the 1990s, fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been reported from many parts of the world, including the United States. The increased prevalence of QRNG in Asia (where prevalence in several countries exceeds 40%), the Pacific Islands, Hawaii, and California, prompted CDC to recommend that fluoroquinolones not be used to treat patients with gonorrhea acquired in these areas with high QRNG prevalence. Preliminary data collected during January-September 2003 from all GISP sites indicating an increase in QRNG among men who have sex with men (MSM) led CDC to recommend in early 2004 that fluoroquinolones not be used to treat patients who are MSM." -- p. 1.
  • Content Notes:
    Division of STD Prevention, prepared by Susan A. Wang, Alesia B. Harvey, Katrina Park, Alicia Edwards, Susan M. Conner, Joan Knapp, Manhar Parekh, Hillard Weinstock and LuEtta Schneider.

    Includes bibliographical references (p. 10-12).

  • Subjects:
  • Document Type:
  • Name as Subject:
  • Genre:
  • Place as Subject:
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at